Nierenbeteiligung im Rahmen von Großgefäßvaskulitiden

Nordborg E, Bengtsson BA (1990) Epidemiology of biopsy-proven giant cell arteritis (GCA). J Intern Med 227:233–236 Reinhold-Keller E, Zeidler A, Gutfleisch J et al (2000) Giant cell arteritis is more prevalent in urban than in rural populations: results of an epidemiological study of primary systemic vasculitides in Germany. Rheumatology (Oxford) 39:1396–1402 Hunder GG, Allen GL (1978) Giant cell arteritis: a review. Bull Rheum Dis 29:980–986 Salvarani C, Gabriel SE, O’Fallon WM, Hunder GG (1995) The incidence of giant cell arteritis in Olmsted County, Minnesota: apparent fluctuations in a cyclic pattern. Ann Intern Med 123:192–194 Bengtsson BA (1991) Epidemiology of giant cell arteritis. Baillière’s Clin Rheumatol 5:379–385 Aiello PD, Trautmann JC, McPhee TJ et al (1993) Visual prognosis in giant cell arteritis. Ophthalmology 100:550–555 Evans JM, O’Fallon WM, Hunder GG (1995) Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. A population-based study. Ann Intern Med 122:502–507 Wagner AD, Andresen J, Raum E et al (2005) Standardised work-up programme for fever of unknown origin and contribution of magnetic resonance imaging for the diagnosis of hidden systemic vasculitis. Ann Rheum Dis 64:105–110 Klein RG, Hunder GG, Stanson AW, Sheps SC (1975) Large artery involvement in giant cell (temporal) arteritis. Ann Intern Med 83:806 Moraga, Sicilia JJ, Blanco J, Ubeda I (2001) Giant cell arteritis and renal amyloidosis: report of a case. Clin Nephrol 56:402–406 Escriba A, Morales E, Albizua E et al (2000) Secondary (AA-type) amyloidosis in patients with polymyalgia rheumatica. Am J Kidney Dis 35:137–140 Altiparmak MR, Tabak F, Pamuk ON et al (2001) Giant cell arteritis and secondary amyloidosis: the natural history. Scand J Rheumatol 30:114–116 Stebbing J, Buetens O, Hellmann D, Stone J (1999) Secondary amyloidosis associated with giant cell arteritis/polymyalgia rheumatica. J Rheumatol 26:2698–2700 Strasser F, Hailemariam S, Weinreich T et al (2000) Giant cell arteritis „causing“ AA-amyloidosis with rapid renal failure. Schweiz Med Wochenschr 130:1606–1609 Estrada A, Stenzel TT, Burchette JL, Allen NB (1998) Multiple myeloma-associated amyloidosis and giant cell arteritis. Arthritis Rheum 41:1312–1317 Logar D, Rozman B, Vizjak A et al (1994) Arteritis of both internal carotid arteries in a patient with focal crescentic glomerulonephritis and antineutrophil cytoplasmic antibodies (c-ANCA). Br J Rheumatol 33:167–169 Muller E, Schneider W, Kettritz U et al (2004) Temporal ateritis with pauci-immune glomerulonephritis: a systemic disease. Clin Nephrol 62:384-386 Tanaka A, Tsujimoto I, Ito Y et al (2011) Temporal artery involvement in microscopic polyangitis. Intern Med 50:1033–1037 Ogawa O, Watanabe R, Shimizu H, Masani F (2011) Hypertensive crisis in young woman with Takayasu arteritis. Intern Med 50:1963–1967 Wada Y, Nishida H, Kohno K et al (1999) AA amyloidosis in Takayasu’s arteritis-long-term survival on maintenance haemodialysis. Nephrol Dial Transplant 14:2478–2481 Koga T, Nishino Y, Makiyama J et al (2010) Serum amyloid A is a useful marker to evaluate the disease activity of Takayasu’s arteritis. Rheumatol Int 30:561–563 Cavatorta F, Campisi S, Trabassi E et al (1995) IgA nephropathy associated with Takayasu’s arteritis: report of a case and review of the literature. Am J Nephrol 15:165–167 Li XM, Ye WL, Wen YB et al (2009) Glomerular disease associated with Takayasu arteritis: 6 cases analysis and review of the literature. Chin Med Sci J 24:69–75 Saxe PA, Altman RD (1992) Takayasu’s arteritis syndrome associated with systemic lupus erythematosus. Semin Arthritis Rheum 21:295–305 Kitazawa K, Joh K, Akizawa T (2008) A case of lupus nephritis coexisting with podocytic infolding associated with Takayasu’s arteritis. Clin Exp Nephrol 12:462–466 Sano N, Kitazawa K, Totsuka D et al (2002) A case of lupus nephritis with alteration of the glomerular basement membrane associated with Takayasu’s arteritis. Clin Nephrol 58:161–165 Jghaimi F, Kabbaj A, Essaadouni L (2010) Takayasu’s arteritis and retroperitoneal fibrosis: a case report. Rev Med Interne 31:1–3 Wagner AD (2011) Einsatz von Biologics bei Vaskulitiden großer Gefäße. In: Hellmich B (Hrsg) Biologics in der Therapie der Vaskulitiden. Uni-Med Verlag, Bremen, S 60–62 Young BR, Cook BE Jr, Bartley GB et al (2004) Initiation of glucocorticoid therapy: before and after temporal artery biopsy. Mayo Clin Proc 79:483–491 Penn H, Dasgupta B (2003) Giant cell arteritis. Autoimmun Rev 2:199–203 Mazlumzadeh M, Hunder GG, Easley KA et al (2006) Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum 54:3310–3318 Salvarani C, Cantini F, Niccoli L et al (2005) Acute-phase reactants and the risk of relaps/recurrence in polymyalgia rheumatica: a prospective follow up study. Arthritis Rheum 53:33–38 Nesher G, Berkun Y, Mates M et al (2004) Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteriitis. Athritis Rheum 50:1332–1337 Hoffman GS, Cid MC, Hellmann DB for the International Network for the Study of Systemic Vasculitides (2002) A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 46:1309–1318 Jover JA, Hernandez-Garcia C, Morado IC et al (2001) Combined treatment of giant cell arteritis with methotrexate and prednisolone: a randomised, double blind, placebo-controlled trial. Ann Intern Med 134:106–114 Mahr AD, Jover JA, Spiera RF et al (2007) Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum 56:2789–2797 Hoffman GS, Cid MC, Weyand CM et al for the Infliximab-GCA Study Group (2007) Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis. Ann Intern Med 146:621–630 Martinez-Taboada VM, Rodriguez-Valverde V et al (2008) A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis 67:625–630 Hernandez-Rodriguez J, Segarra M, Vilardell C et al (2004) Tissue production of pro-inflammatory cytokines (IL-1β, TNFα and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. Rheumatology (Oxford) 43:294–301 Cantini F, Niccoli L, Salvarani C et al (2001) Treatment of longstanding active giant cell arteritis with infliximab: report of four cases. Arthritis Rheum 44:2933–2935 Salvarani C, Cantini F, Niccoli L et al (2003) Treatment of refractory polymyalgia rheumatica with infliximab: a pilot study. J Rheumatol 33:760–763 Catanoso MG, Macchioni PL, Boiardi L et al (2007) Treatment of refractory polymyalgia rheumatica with etanercept: an open pilot study. Arthritis Rheum 57:1514–1519 Roche NE, Fulbright JW, Wagner AD et al (1993) Correlation of interleukin 6 production and disease activity in polymyalgia rheumatica and giant cell arteritis. Arthritis Rheum 36:1286–1294 Strand V, Yazici Y (2007) Interleukin-6 inhibition. Tolerability profile and clinical implications. Bull NYU Hosp JT Dis 65(Suppl 1):S21–24 Beyer C, Axmann R, Sahinbegovic E et al (2011) Anti-interleukin 6 receptor therapy as rescue treatment for giant cell arteritis. Ann Rheum Dis 70:1874–1875 Bhatia A, Ell PJ, Edwards JCW (2005) Anti-CD20 monoclonal antibody (rituximab) as an adjunct in the treatment of giant cell arteritis. Ann Rheum Dis 64:1099–1100 Jones RB, Tervaert JW, Hauser T et al (2010) Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 363:211–220 Stone JH, Merkel PA, Spiera R et al (2010) Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363:221–232 Liang P, Hoffman GS (2005) Advances in the medical and surgical treatment of Takayasu arteritis. Curr Opin Rheumatol 17:16–24 (Review) Hoffman GS, Merkel PA, Brasington Rd et al (2004) Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum 50:2296–2304 Hoyer BF, Mumtaz IM, Loddenkemper K et al (2012) Takayasu arteritis is characterized by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab. Ann Rheum Dis 71:75–79 Both M, Moosig F, Gross WL et al (2009) Großgefäßvaskulitiden. Radiologe 49:947–966